Abstract:DNA damage response and repair (DDR) gene alterations increase tumor-infiltrating lymphocytes, genomic instability, and tumor mutational burden (TMB). Whether DDR-related alterations relate to therapeutic response and prognosis in lung cancer lacking oncogenic drivers remains unknown. Pretherapeutic cancer samples of 122 patients [86 non-small cell lung cancer and 36 small cell lung cancer (SCLC)] harboring no EGFR/ALK alterations were collected. Through whole-exome sequencing, we outlined DDR mutational landscape and determined relationships between DDR gene alterations and TMB or intratumoral heterogeneity. Then, we evaluated the impacts of DDR gene alterations on therapeutic response and prognosis and established a DDR-based model for prognosis prediction. In addition, we investigated somatic interactions of DDR genes and immunomodulatory genes, immune expression patterns, immune microenvironment, and immune infiltration characteristics between DDR-deficient and DDR-proficient samples. Samples from cBioportal datasets were utilized for verification. We found that deleterious DDR gene alterations were closely associated with higher TMB than proficient-types ( p < 0.001). DDR mechanisms attach great importance to the determination of patients’ prognosis after chemotherapy, and alterations of base excision repair pathway in adenocarcinoma, nucleotide excision repair in squamous carcinoma, and homologous recombination pathway in SCLC tend to associate with worse progression-free survival to first-line chemotherapy (all p < 0.05). A predictive nomogram model was constructed incorporating DDR-related alterations, clinical stage, and smoking status, with the area under curve values of 0.692–0.789 for 1- and 2-year receiver operating characteristic curves in training and testing cohorts. Furthermore, DDR-altered tumors contained enhanced frequencies of alterations in various genes of human leukocyte antigen (HLA) class I pathway including TAP1 and TAP2 than DDR-proficient samples. DDR-deficient types had lower expressions of STING1 ( p = 0.01), CD28 ( p = 0.020), HLA-DRB6 ( p = 0.014) in adenocarcinoma, lower TNFRSF4 ( p = 0.017), and TGFB1 expressions ( p = 0.033) in squamous carcinoma, and higher CD40 ( p = 0.012) and TNFRSF14 expressions (p = 0.022) in SCLC. DDR alteration enhanced activated mast cells in adenocarcinoma ( p = 0.044) and M2 macrophage in squamous carcinoma ( p = 0.004) than DDR-proficient types. Collectively, DDR gene alterations in lung cancer without oncogenic drivers are positively associated with high TMB. Specific DDR gene alterations tend to associate with worse progression-free survival to initial chemotherapy.

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer

DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients

PATH01.03 Mutational Landscape and Prognosis Prediction for Immune Checkpoint Blockades of DNA Damage Response Pathways in Non-Small Cell Lung Cancer

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

MA15.03 The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC

Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy

Clinical Significance of DNA Damage Response Mutations in Stage I and Stage IIIa NSCLC

Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study

DNA Damage Response and Repair Gene Alterations Increase Tumor Mutational Burden and Promote Poor Prognosis of Advanced Lung Cancer

PD-L1 Expression and Its Effect on Clinical Outcomes of EGFR-mutant NSCLC Patients Treated with EGFR-TKIs

Deleterious Alterations Of Dna Damage Response And Repair (Ddr) Genes In Association With Clinical Benefit To Programmed Cell Death Protein-1 (Pd-1)/Pd Ligand 1 (Pd-L1)-Based Therapy In Esophageal Squamous Cell Carcinoma (Escc)

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

JCSE01.23 Specific TP53 Mutation Subtypes As Biomarker for Response to PD-1/L1 Blockade Immunotherapy in NSCLC

Impact of TP53 Mutations on Efficacy of PD-1 Targeted Immunotherapy in Non-Small Cell Lung Cancer (NSCLC).

DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Exploring Genomic Biomarkers for Pembrolizumab Response: A Real-World Approach and Patient Similarity Network Analysis Reveal DNA Response and Repair Gene Mutations as a Signature

Association of PTPRD/PTPRT Mutation With Better Clinical Outcomes in NSCLC Patients Treated With Immune Checkpoint Blockades

Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer

Identification and validation of tissue or ctDNA PTPRD phosphatase domain deleterious mutations as prognostic and predictive biomarkers for immune checkpoint inhibitors in non-squamous NSCLC

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer